Engineered bacteria as an orally administered anti-viral treatment and immunization system.

EcN-Spike-treated mice showed variable but generally elevated percentages of CD3 + cells (T cells) ranging from 19.88% to 46.27%, compared to the vaccine group’s range of 22.14% to 84.30%, which exhibited a decreasing trend ( Figure 16(a) ).

also in 47,180 other papers